A carregar...
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
BACKGROUND: Currently, there are no direct comparisons of apixaban and rivaroxaban, two new oral direct factor Xa inhibitors approved for management of thromboembolic disorders. OBJECTIVE: Compare the pharmacokinetics and anti-factor Xa activity (AXA) of apixaban and rivaroxaban. METHODS: In this ra...
Na minha lista:
| Publicado no: | Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4235474/ https://ncbi.nlm.nih.gov/pubmed/25419161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S61131 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|